To investigate the association between early hyperglycemia and growth and development from hospital discharge to 2 years corrected age (CA) in very low birth weight (VLBW) infants. STUDY DESIGN: Blood glucose levels during the first 14 days after birth, weight, length and occipital-frontal circumference (OFC) at birth, hospital discharge and 4, 12 and 24 months CA, Bayley developmental scores at 12 and 24 months CA, and information on multiple clinical variables were recorded on VLBW preterm infants (N ¼ 80). The relationships between hyperglycemia, growth and developmental scores were determined using linear mixed effects regression. RESULT: Hyperglycemia was a strong predictor of poor rate of increase in weight, length and OFC until 24 months CA. Hyperglycemia was not associated with lower scores on the Bayley scales. CONCLUSION: Neonatal hyperglycemia was associated with poor physical growth until at least 2 years CA in this cohort of VLBW preterm infants.
INTRODUCTION
Hyperglycemia is common among very low birth weight (VLBW) preterm infants. 1 A recent study using continuous glucose monitoring confirmed that as many as 80% of VLBW infants experience elevated glucose levels during the first week of life and that the risk of developing hyperglycemia is inversely related to gestational age and birth weight. 2 Hyperglycemia has been associated with increased mortality and morbidity in preterm infants, including retinopathy of prematurity (ROP), [3] [4] [5] sepsis, 6, 7 severe intraventricular hemorrhage (IVH) and prolonged hospital stay. 1 However, little has been documented on the long-term effects of hyperglycemia on growth and development. Determining potentially modifiable risk factors for poor growth is especially important given the association between poor postnatal weight gain and worsened long-term neurodevelopmental outcome in VLBW preterm infants, which has been confirmed by several large, multi-center studies. 8, 9 Until recently there had been no reports of an association between early life hyperglycemia and long-term neurodevelopment. However, it was recently shown that VLBW infants with hyperglycemia had a higher incidence of neurological and behavioral problems. 7 That study was limited by the use of broad categories of neurologic outcomes observed by multiple physicians, and standardized test scores were not available. 7 Treatment of hyperglycemia in VLBW preterm infants varies among centers and typically consists of some combination of restriction of glucose infusion rate and insulin administration. 10 To our knowledge, the influence of these varied treatment regimens on long-term growth and neurodevelopment have also not been explored.
The goal of our study was to examine the associations between early hyperglycemia and growth in weight, length, occipital-frontal head circumference (OFC), and Bayley Development Scales in appropriate for gestational age VLBW preterm infants from birth to approximately 2 years corrected age (CA), controlling for several important covariates. A cross-sectional analysis was also performed, examining hyperglycemia as a predictor of ROP, IVH and sepsis, controlling for birth weight.
METHODS
The design of the study was a retrospective review of infants born between January 2003 and July 2007 and followed in the neonatal intensive care unit (NICU) Follow-up Program at the University of Minnesota Amplatz Children's Hospital in Minneapolis, MN, USA. Approval for this study was obtained from the University of Minnesota Institutional Review Board. The subjects were 80 appropriate for gestational age VLBW preterm infants (50% male) born before 30 weeks gestation. Associations between linear growth and cognitive outcomes in this cohort have been published elsewhere.
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The infants were followed daily, while inpatient, by the neonatal nutrition support service. Clinical care, including insulin use, was at the discretion of the attending neonatologist and nutritional management was jointly agreed on by the neonatologist and the nutrition support service. Infants received aggressive nutritional support with enteral feeding goals of 120 kcal kg -1 day -1 and 4 g kg -1 day -1 of protein during their hospitalization. Our usual protocol for treatment of hyperglycemia is to limit the glucose infusion rate to 7 mg kg -1 min -1 and then treat any persistent hyperglycemia with bolus and/or drip insulin therapy. The number of days each infant received any insulin was summed. Each infant was followed in the NICU Follow-Up Clinic for monitoring of growth and development, as well as nutritional management and neurodevelopmental screening at approximately 4 months, 1 year and 2 years CA.
Blood glucose levels were obtained per the care team with a minimum of one morning level obtained on each infant each day. All levels obtained in the first 14 days of life were recorded. A glucose level of 4150 mg dl was considered hyperglycemic, while a glucose level o60 mg dl -1 was considered hypoglycemic after 24 h of age (o50 mg dl -1 for the first 24 h). We chose a conservative level of o60 mg dl -1 , which is recommended for children requiring treatment with insulin, 12, 13 in order to capture any possible negative effects of treatment. For each infant, the number of days of hyperglycemia was summed and entered as a continuous covariate in the regression analyses, and also coded as 0 days, 1 to 4 days, or 5 or more days for graphing purposes to illustrate differences in mean curves of weight, length and OFC. For the cross-sectional analysis reported below, the total number of days of hypoglycemia was summed for each participant.
Infant's weight, recumbent length and head circumference were recorded at birth, hospital discharge, 4, 12 and 24 months CA. Measurements were taken by a single nurse at each visit throughout the study. Length was measured using a flexible cloth measuring tape at birth and hospital discharge and a standard infant length board at each subsequent follow-up visit to the nearest 0.1 cm. Head circumference was measured using a flexible cloth measuring tape at all-time points to the nearest 0.1 cm. Data were gathered on multiple morbidities during hospitalization. Total hospital caloric deficit was calculated using a 120 kcal kg -1 day -1 goal and subtracting or adding the actual amount of kcals received daily. Data on the number of days taken to attain full enteral feeds (120 kcal kg -1 day -1
), number of inpatient days requiring positive pressure ventilation, oxygen therapy, antibiotic and steroid therapy were also collected as covariates.
ROP diagnosis was recorded as the most severe stage diagnosed before discharge. IVH diagnosis and number of episodes of culture-positive sepsis were also recorded. The Bayley Scales of Infant Development-Third Edition (hereafter referred to as 'Bayley scales') was administered by a single pediatric neuropsychologist at 12 and 24 months CA in the NICU FollowUp Clinic.
Cross-sectional analysis
Logistic regression models were used to assess the association of hyperglycemia (days) with ROP stage 42 (coded as yes/no) and IVH, which was coded as 'low' (grades 0 to II), or 'high' (grades III to IV). Poisson regression was used to assess the association of hyperglycemia (days) with sepsis (coded as number of episodes).
Longitudinal analysis
Linear mixed effects regression (LMER) 14 was used to examine the association of hyperglycemia, caloric deficit and other covariates with initial status and growth of infant weight, length and OFC (considered separately). LMER was also used to examine the association of the predictors with the Bayley scales. Preliminary exploration of the relationship of weight, length and OFC with CA (data not shown) indicated the need for non-linear growth curves for these variables. Bayley scales were only measured at two times points (12 and 24 months) and thus, linear curves were used. Non-linearity was accounted for using fractional polynomial transformations of CA. 15 Model selection using Akaike's information criterion indicated the need for the square root transformation of CA for weight and length (that is, ffiffiffiffiffiffi CA p was the predictor), and the natural log transformation for OFC (that is, log e (CA) was the predictor). These transformations allow the modeling of non-linear but monotonic growth curves using a minimum of parameters. 16 In addition to transformed CA, we examined the baseline predictors of birth weight, hyperglycemia, hypoglycemia, caloric deficit and days requiring therapy with insulin, positive pressure ventilation, oxygen, antibiotics and steroids; IVH was also included for the analysis of the Bayley scales. For each outcome variable, a LMER model was fit with the aforementioned predictors, and the focus was on intercept effects (that is, differences in initial status) and slope effects (that is, differences in trajectories). An intercept effect in LMER is specified by including a predictor as a single effect (main effect), and a slope effect is specified by including the predictor by time interaction (for example, birth weight Â ffiffiffiffiffiffi CA p ). 17 Each LMER model included two random effects, one for intercepts and one for slopes. Typical normality assumptions were made about the random effects and random error.
14 The likelihood ratio test was used for omnibus effects (intercepts, slopes), and individual parameter estimates were evaluated with z-ratios, equal to the parameter estimates divided by their standard errors. The criterion of Pp0.05 was used for statistical significance in all cases.
All analyses were performed using R 2.12. 18 The cross-sectional analysis was carried out using the glm() function. The longitudinal analysis was carried out using the lmer() function from the lme4 package. 19 All models were estimated using maximum likelihood methods. Such methods provide unbiased estimates under an ignorable missing data mechanism. 20 
RESULTS
A total of 289 VLBW preterm infants were admitted to the NICU during the time period; exclusions included small for gestational age (n ¼ 29), large for gestational age (n ¼ 9), transfer to another hospital (n ¼ 93) and incomplete follow-up (n ¼ 78). The sample of infants included in this analysis make up B27% of the total infants admitted to the NICU during this time period and are similar to the entire population in mean weight, length and head circumference at birth and hospital discharge. All infants were followed to 1-year CA and 62 (78%) were followed to 2 years CA. Infants followed to 2 years of age (noted as subscript 2, below) were similar to those followed only to 1 year (noted as subscript 1, below), being statistically equivalent in birth weight ((gm) Birth characteristics, as well as data on the hospital course and 2-year outcomes of the cohort are detailed in Table 1 . Hyperglycemia (4150 mg dl -1 ) during the first 2 weeks of life was found in 77% of the infants.
Cross-sectional analysis Controlling for birth weight, hyperglycemia was a statistically significant predictor of ROP4stage 2, z ¼ 2.39, P ¼ 0.02. Hyperglycemia was also a significant predictor of number of episodes of sepsis, z ¼ 5.90, Po0.001. Hyperglycemia was not a significant predictor of IVH, z ¼ 0.64, P ¼ 0.53.
Longitudinal analysis
Results of the longitudinal analysis for the physical outcome variables (weight, length and OFC) are shown in Table 2 . The bottom of the table shows there was an omnibus effect of the set of predictors for initial differences (intercepts) and for prediction of growth (slopes) in all the outcomes. The upper portion of the table presents the parameter estimates for each of the variables included in the models. The intercept effects of the predictors are contained in rows 3 to 12 of the table and the slope effects are contained in rows 13 to 22. As seen in the table, hyperglycemia was a statistically significant predictor of growth for all three outcomes (row 16). The sign of the hyperglycemia by slope interaction was negative, indicating that greater number of days of hyperglycemia were associated with slower rates of growth controlling for all other variables. This phenomenon is illustrated in Figure 1 . Figure 1 shows weight as a function of CA. Individuallevel growth curves are shown in gray, and the fitted model curves for infants with 0, 1 to 4, and 5 or more days of hyperglycemia are shown in black. Infants with hyperglycemia were slightly larger at estimated date of confinement, but these differences were very small. There was a dramatic dose-response relationship between number of days of hyperglycemia and weight rate of growth, with infants who did not experience hyperglycemia (0 days) having the fastest growth. The figure shows that by 24 months, infants with 5 þ days of hyperglycemia were predicted to be B2 kg lighter than infants with 0 days of hyperglycemia. Figure 1 shows similar results for length and OFC as a function of CA. There was again a dramatic dose-response relationship between hyperglycemia and length and head growth (slope), with infants who did not experience hyperglycemia (0 days) having the fastest growth. These figures show that by 24 months, infants with 5 þ days of hyperglycemia were predicted to be B5 cm shorter and have a B2.5 cm smaller OFC than infants with 0 days of hyperglycemia. Table 3 shows the results of the Bayley scales analysis. The bottom of the table shows the omnibus tests were statistically significant for prediction of Bayley scale scores at 12 months (initial status), but not significant for prediction of Bayley scale score changes from 12 to 24 months (Table 3) . Associations with developmental outcomes were generally weaker than with growth outcomes. However, there was an association between days on antibiotics and hyperglycemia with the cognitive score intercept. Caloric deficit and days requiring positive pressure ventilation were associated with poorer language scores (Po0.01), whereas only IVH was associated with decreased motor scores (Po0.001).
DISCUSSION
Hyperglycemia was very common in this cohort of VLBW preterm infants. The results of this study demonstrate that early hyperglycemia was predictive of rate in physical growth (weight, length and OFC) adjusting for a number of covariates (insulin, birth weight, hypoglycemia, caloric deficit and days requiring therapy with insulin, positive pressure ventilation, oxygen, antibiotics and steroids). Individuals who had 1 or more days of hyperglycemia had a slower rate of physical growth over the observed time span than those who did not experience hyperglycemia (see Figure 1) . This is the first study to show a link between early hyperglycemia and long-term growth in VLBW preterm infants, as well as documenting the contribution of possible treatment modalities (caloric restriction vs insulin use) to this diminished growth velocity. This study is also unique, in that we have collected standardized neurodevelopmental scores. Our study shows a significant negative association between early hyperglycemia and caloric deficit with long-term growth velocity. Not surprisingly, infants with the greatest degree of caloric restriction had a much slower rate of growth in weight, length and OFC and continued to be significantly smaller in all three dimensions at 24 months CA and beyond. However, we also found that infants who experienced hyperglycemia grew slower and remained smaller, even when controlling for caloric restriction, insulin use and multiple other markers of illness and inflammation. Insulin use, when controlling for other factors, did not have a statistically significant association with growth velocity in this sample.
To our knowledge, there is only one other study evaluating the effects of early hyperglycemia on long-term growth outcomes in preterm infants. Van der Lugt et al. 7 reported no differences in weight, length or head circumference at 2 years CA between those infants with and without hyperglycemia. The infants in that study were larger at birth (1323 vs 943 g) and more mature (29.4 vs 27.1 weeks) than the infants in our population. Therefore, the difference in results may reflect the greater vulnerability of smaller, more immature infants to the effects of early hyperglycemia. The Van der Lugt study also looked only at one time point instead of growth velocity over time as we have presented, and no nutritional data were presented. 7 Given the strong association that we found between calorie deficit and long-term growth, this may be a relevant source for the difference in our results. It is possible that not controlling for nutritional variation among infants masks the subtler effect of hyperglycemia.
The pathophysiology of diminished long-term growth in infants with hyperglycemia is unclear. We speculate that it may be secondary to increased free radical production, as glucose is thought to be proinflammatory and an inducer of oxidative stress. 21 Another possible explanation, specifically for the diminished linear growth, may be the association between relative insulin deficiency and low insulin-like growth factor-1 levels. 21 This association between hyperglycemia, increased inflammatory markers and reduced insulin-like growth factor-1 levels has been previously documented in adolescents with type 1 diabetes mellitus. 22, 23 Finally, it is possible that hyperglycemia is a sign of altered metabolism in this group of infants, which then leads to poor growth later in life. Although lowering glucose infusion rate can be an effective method of glucose control it clearly has a negative impact on caloric intake 10 and may lead to suboptimal postnatal growth. Given the association of poor growth with long-term development, 8, 9 this may not be the optimal method of management. In contrast, we did not find any association between long-term growth and insulin usage. This is in contrast to a recent study by Alsweiler et al. 24 who found that tighter glucose control using insulin led to increased rate of weight gain and OFC growth, but decreased rate of linear growth at 36 weeks postmenstrual age. The long-term effect on growth and neurodevelopment was not assessed. As infants in our unit are managed with a combination of caloric restriction and insulin therapy, it is difficult to determine which modality is most effective at promoting long-term growth and further prospective studies are needed.
Our results indicate that hyperglycemia, after controlling for other factors, did not adversely affect neurodevelopmental outcomes at 24 months CA. In fact, there is an unexplained and unexpected finding of a positive association between cognitive scores and hyperglycemia. One previous study has indicated an inverse association between early hyperglycemia and neurodevelopmental outcomes at 24 months, however, that study used multiple evaluators and lacked standardized and multidimensional neurobehavioral outcome measures as collected in the present investigation. 7 Larger, prospective trials using objective developmental testing are necessary to better understand the effects of hyperglycemia on brain growth and development.
In addition to the association with long-term growth, our study also confirmed the findings of others that early hyperglycemia is associated with increased episodes of sepsis and ROP [3] [4] [5] [6] [7] and not with severe IVH. 5 Our study is limited by its retrospective nature and to a lesser extent by the use of multiple strategies to treat hyperglycemia including both caloric restriction and insulin usage, which makes it very difficult to parse the independent effects of either of these possible mediators on our outcomes. In future prospective studies it will be important to carefully document protein intake, as well as outpatient nutrition, as these variables likely also have an important role in long-term growth. Given the present uncertainty regarding the best treatment strategies for neonatal hyperglycemia, it is clear that additional prospective study of the long-term effects of this common condition and its treatment is vital to optimizing long-term outcomes.
CONCLUSIONS
Hyperglycemia not only increases short-term morbidity in VLBW preterm infants, but may also have a lasting effect on weight, length and head growth to at least 24 months CA and perhaps beyond. However, it appears that the most important predictor of this poor growth is the degree of nutritional deficit, possibly accrued as a consequence of therapy for hyperglycemia. These findings suggest that further research is needed to identify the optimal strategy for management of hyperglycemia in the NICU. Our study was unable to confirm a negative association between early hyperglycemia and later neurodevelopment, although further prospective studies are needed in this high-risk population.
